DELTAGEN INC

DELTAGEN INC

Previous company name

Name change date

Company Overview
Deltagen, Inc. is a US-based company engaged in the provision of drug discovery tools and services. The company was established in 1997. Its registered office address is located in Redwood City, California.
Deltagen is a leading provider of drug discovery tools and services to the biopharmaceutical industry. Deltagen offers a suite of programs designed to enhance the efficiency of drug discovery including access to biological models as well as both small-molecule and secreted protein drug targets. In addition, Deltagen offers extensive target validation data in the areas of immunology and metabolic diseases. Deltagen’s products and programs have been validated by customers such as Eli Lilly & Co., GlaxoSmithKline, Merck & Co., Millennium Pharmaceuticals and Pfizer.
Deltagen’s unique systems biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. The company’s DeltaOne, delivers per-gene knockout mice. The company also offers DeltaBase, a comprehensive searchable database of in vivo-derived mammalian gene function information and gene targets.
Since late 2005, Deltagen has had collaboration with Charles River Laboratories of Wilmington, a global provider of solutions that advance the drug discovery and development process for the biopharmaceutical industry.
Business Summary
Deltagen, Inc. uses in-vivo derived mammalian gene function information to define the function and disease relevance of mammalian genes for the purposes of discovering and validating novel drug targets. The Company’s products, based on its platform technology, provide databases of in-vivo mammalian gene function information on target genes of interest to drug researchers. The customers and partners include companies, such as Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc. and Schering-Plough Research Institute, as well as biotechnology and biopharmaceutical companies, including Millennium Pharmaceuticals, Tanox, Inc., Nuvelo, Inc. and Lexicon Genetics Incorporated. In June 2003, the Company filed a voluntary petition for protection under Chapter 11 of the United States Bankruptcy Code. In December 2009, the Company acquired Benten BioServices, Inc.
Description and history
Deltagen, Inc., incorporated in 1997, uses in-vivo-derived mammalian gene function information to define the function and disease relevance of mammalian genes for the purposes of discovering and validating novel drug targets. The proprietary information platform serves pharmaceutical partners and customers in their efforts to discover potential new drug therapies. The Company’s products, based on its platform technology, provide databases of in-vivo mammalian gene function information on target genes of interest to drug researchers. The current customers and partners include many pharmaceutical companies, such as Eli Lilly and Company, GlaxoSmithKline plc, Merck & Co., Inc., Pfizer Inc. and Schering-Plough Research Institute, as well as biotechnology and biopharmaceutical companies, including Millennium Pharmaceuticals, Tanox, Inc., Nuvelo, Inc. and Lexicon Genetics Incorporated. The Company has developed, and plans to continue to develop, technologies, products and programs that elucidate the function and disease relevance of genes in mammalian organisms. In December 2009, the Company acquired Benten BioServices, Inc.

DeltaBase is the proprietary database that provides information, based on knockout mouse studies, on gene function for drug discovery. It created DeltaBase to be marketed to the pharmaceutical and biotechnology industries to help define the role that genes play in biological processes and disease. DeltaBase has been expanding by the addition of approximately 250 different mammalian genes each year. Genes are selected for DeltaBase based on their potential to become useful drug targets. Deltagen designed DeltaBase to provide subscribers with the ability to compare resulting phenotypic and gene function data across hundreds of different mammalian genes from different gene families selected for their potential commercial relevance to drug discovery.

In May 2001, the Company entered into a DeltaBase access agreement with Vertex. Under the agreement, Vertex received non-exclusive access to a subset of DeltaBase that contains in-vivo mammalian gene function information on kinases, proteases and certain other gene families. In February 2003, it received notice that Vertex was terminating the agreement.

Deltagen launched a product line known as DeltaOne that offers access to the DeltaBase portfolio of knockout mice and/or accompanying phenotypic data, as well as any corresponding intellectual property, on a gene-by-gene basis. The customers include Aventis Pharmaceuticals, Euroscreen S.A. and Millennium Pharmaceuticals.

In August 2001, the Company entered into a secreted protein agreement with Eli Lilly (Lilly) to evaluate, and potentially develop and commercialize, therapeutic secreted proteins. Under the terms of the agreement, Lilly has provided potential targets from its secreted protein pipeline for which it will further evaluate the therapeutic potential in mammalian models. Among those secreted proteins with potential therapeutic value, each company may select proteins for commercial development, with each company receiving royalties based on sales of therapeutic products. The agreement provides Lilly with certain acquisition, co-promotion, co-marketing and profit-sharing options with respect to therapeutic products developed and commercialized by the Company.

In October 2001, Deltagen entered into a collaboration agreement with Nuvelo, formerly Hyseq, to research, develop and commercialize biopharmaceutical products based on secreted proteins. Under the terms of the agreement, Nuvelo has provided Deltagen with gene sequences encoding secreted proteins and it will utilize the proprietary in-vivo mammalian gene knockout technology to discover and validate potential commercially relevant biopharmaceutical drug targets.

DeltaSelect is the custom gene knockout program that uses the platform technology employed in the DeltaBase database program. The DeltaSelect program is different, however, because customers select and identify to the Company the particular genes that they wish to have knocked out in mice. Deltagen provides customers with access to gene knockout technologies and the resulting knockout mice, data and information generated under each DeltaSelect program.

The Company faces significant competition in the area of genomics-based research from for-profit companies such as Celera Genomics, Curagen, Inc., Exelixis, Inc., GeneLogic, Inc., Human Genome Sciences, Inc., Incyte Pharmaceuticals, Inc., Lexicon Genetics Incorporated and Millennium Pharmaceuticals, Inc. Other competitors include Lexicon Genetics Incorporated, Exelixis, Inc., Nuvelo, Inc., deCODE Genetics Inc. and Devgen N.V. It may also be competing directly with biotechnology drug companies, including Genentech Inc., Amgen Inc. and Abgenix Inc.

Business Line
Engaged in the provision of drug discovery tools and services
Subsidiary
BENTEN BIOSERVICES, INC
Advisor
PATEL & ASSOCIATES
IPO date
8/2000
US SIC Code
2835
Company Address
Suite 105
1900, S. Norfolk Street
City province or state postal code
94403, SAN MATEO, CA
Phone: +1 650 345 7600
Fax:
Country address: UNITED STATES OF AMERICA
Website url: www.deltagen.com